New Zealand

‘Worst-case scenario this is a bump in the road’: Pacific Edge


Cancer diagnostics company’s share price plummets after trading halt lifted.

Two-thirds of Pacific Edge’s US commercial test by volume were for CMS patients in the 2022 financial year.

Shares in dual-listed diagnostics company Pacific Edge have plummeted after the lifting of a trading halt imposed last Friday while the company sought advice on proposed funding reimbursement changes in the US.

The share price has dropped 41% to 46c so far in trading today, after earlier hitting a

Want to read more? It’s easy.

Choose your best value subscription option

Individual

Group membership

NBR Marketplace

NZ Aviation News

Yearly Premium Online Subscription

NZ$449.00 / yearly

Monthly Premium Online Subscription

NZ$39.00 / monthly

Smartphone Only Subscription

NZ$18.95 / monthly

Premium Group Membership 10 Users

NZ$300+GST / monthly

$30 per user – Pay by monthly
credit card debit

Premium Group Membership 20 Users

NZ$500+GST / monthly

$25 per user – Pay by monthly
credit card debit

Premium Group Membership 50 Users

NZ$1000+GST / monthly

$20 per user – Pay by monthly
credit card debit

Premium Group Membership 100 Users

NZ$1500+GST / monthly

$15 per user – Pay by monthly
credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$449.00 / yearly

Aviation News – Monthly

NZ$8.95 / monthly

Already have an account? Login

Contact the Writer: fiona@nbr.co.nz

© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.



Source link

Leave a Reply

Your email address will not be published.